Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Tinlarebant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Belite Bio Announces Participation at 41st APAO Congress
    Belite Bio Announces Participation at 41st APAO Congress

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3228538/0/en/Belite-Bio-Announces-Participation-at-the-41st-Asia-Pacific-Academy-of-Ophthalmology-Congress-APAO.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    Belite Bio Finishes Enrolling Patients In Tinlarebant Trial
    Belite Bio Finishes Enrolling Patients In Tinlarebant Trial

    27 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/27/3226453/0/en/Belite-Bio-Completes-Enrollment-in-the-DRAGON-II-Clinical-Trial-of-Tinlarebant-for-Stargardt-Disease-STGD1.html

    GLOBENEWSWIRE
    27 Jan 2026
    Share Share
    Belite Brings FDA Filing Into View with Phase 3 Stargardt Win
    Belite Brings FDA Filing Into View with Phase 3 Stargardt Win

    01 Dec 2025

    // PRESS RELEASE

    https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite

    PRESS RELEASE
    01 Dec 2025
    Share Share
    Belite Bio Reports Q3 2025 Financial Results & Corporate Update
    Belite Bio Reports Q3 2025 Financial Results & Corporate Update

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184490/0/en/Belite-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share
    Belite Bio Gets Conditional UK Approval For Tinlarebant
    Belite Bio Gets Conditional UK Approval For Tinlarebant

    02 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/02/3178795/0/en/Belite-Bio-Announces-UK-s-Medicines-and-Healthcare-Products-Regulatory-Agency-Agrees-to-Conditional-Marketing-Authorization-Application-Based-on-Interim-Analysis-Results-for-the-Tr.html

    GLOBENEWSWIRE
    02 Nov 2025
    Share Share
    Belite Bio Gets Priority Review From China NMPA For Tinlarebant
    Belite Bio Gets Priority Review From China NMPA For Tinlarebant

    15 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/15/3167044/0/en/Belite-Bio-Announces-China-NMPA-Agrees-to-New-Drug-Application-with-Priority-Review-based-on-Interim-Analysis-Results-for-the-Treatment-of-Stargardt-Disease-with-Tinlarebant.html

    GLOBENEWSWIRE
    15 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.